Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NATUS MEDICAL INCORPORATED

(NTUS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Bryant M. Moore, Ph.D. and Eric J. Guerin Appointed to Natus Board of Directors

08/18/2021 | 08:31am EST

PLEASANTON, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, today announced the appointments of Bryant M. Moore, Ph.D. and Eric J. Guerin to the Company's Board of Directors. With these appointments, the Natus Board will be expanded to eight members.

“We are pleased to welcome Bryant and Eric to the Natus Board and look forward to benefitting from their medical device experience and business counsel as we move beyond ‘One Natus’ to a more focused growth-oriented strategy,” said Joshua H. Levine, Chairperson of the Board of Directors.

Dr. Moore has served as the Director of Strategic partnerships at the University of North Carolina's Office of Technology Commercialization since 2015. Prior to his current role, Dr. Moore served as the Global Head of Refractive R&D at Abbott Laboratories and he served in multiple leadership roles in research and development at Medtronic. Dr. Moore brings decades of significant leadership experience in technology assessment, research, new product development, and platform technology management that will support Natus’ efforts in innovation and portfolio management.

“I am excited to join the Natus Board and help the Company achieve long term growth through a robust innovation pipeline complemented by external acquisition,” said Dr. Moore.

Mr. Guerin serves as Chief Financial Officer of CDK Global, Inc., the largest provider of automotive dealership solutions including retailing, CRM, financing, parts and service, IT infrastructure and dealership operations. Prior to this current role, Mr. Guerin served in financial leadership and business development roles at Corning Incorporated, Flowserve Corporation, Alcon and Johnson & Johnson. Mr. Guerin brings significant financial and business experience with large, complex medical device organizations as well as experience in innovative service and subscription business models to the Board.

“Natus’ neurodiagnostic portfolio is a market leader, and I am looking forward to joining the Board to help the Company build on its core platforms to offer comprehensive solutions to healthcare customers,” said Mr. Guerin.

“Bryant and Eric are joining Natus at an exciting time and will be invaluable resources to the Company as we strengthen internal product development and other growth-oriented business processes,” said Jonathan Kennedy, President and Chief Executive Officer.

About Natus Medical Incorporated

Natus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Additional information about Natus Medical can be found at www.natus.com.

Natus Medical Incorporated
B. Drew Davies
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com


Primary Logo


ę GlobeNewswire 2021
All news about NATUS MEDICAL INCORPORATED
11/05NATUS MEDICAL INC Management's Discussion and Analysis of Financial Condition and Resu..
AQ
11/04NATUS MEDICAL : Q3 Earnings Snapshot
AQ
11/04Natus Medical Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/04Natus Medical Posts Higher Q3 Adjusted Earnings, Revenue; Narrows Full-Year Revenue Out..
MT
11/04GUIDANCE : (NTUS) NATUS MEDICAL INCORPORATED Expects Fiscal Year 2021 EPS Range $1.13 - $1..
MT
11/04GUIDANCE : (NTUS) NATUS MEDICAL INCORPORATED Expects Q4 EPS Range $0.41 - $0.46
MT
11/04Earnings Flash (NTUS) NATUS MEDICAL INCORPORATED Reports Q3 EPS $0.28, vs. Street Est o..
MT
11/04Earnings Flash (NTUS) NATUS MEDICAL INCORPORATED Reports Q3 Revenue $113.9M, vs. Street..
MT
11/04Natus Medical Announces Third Quarter 2021 Financial Results
AQ
11/04Natus Medical Incorporated Reports Earnings Results for the Third Quarter and Nine Mont..
CI
More news
Financials (USD)
Sales 2021 471 M - -
Net income 2021 23,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 31,4x
Yield 2021 -
Capitalization 743 M 743 M -
Capi. / Sales 2021 1,58x
Capi. / Sales 2022 1,53x
Nbr of Employees 1 420
Free-Float 98,4%
Chart NATUS MEDICAL INCORPORATED
Duration : Period :
Natus Medical Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATUS MEDICAL INCORPORATED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 21,99 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Jonathan A. Kennedy President, Chief Executive Officer & Director
Benjamin Drew Davies Chief Financial Officer & Executive Vice President
Joshua H. Levine Non-Executive Chairman
D. Christopher Chung Chief Medical Officer & VP-Regulatory Affairs
Ivan Pandiyan Vice President-Research & Development
Sector and Competitors